Scientists at Harvard's Wyss Institute have developed DoriVac, a vaccine platform built from self-assembling DNA nanostructures that could replace mRNA vaccines. Published in Nature Biomedical Engineering on March 17, the study shows DoriVac matched Moderna and Pfizer/BioNTech mRNA vaccines in head-to-head mouse comparisons while being more stable and easier to manufacture.
DoriVac uses tiny square DNA structures with adjuvant molecules on one face and pathogen antigens on the other, giving researchers unprecedented control over vaccine composition at the molecular level. In tests targeting spike protein regions shared by SARS-CoV-2, HIV, and Ebola, the platform triggered strong antibody and T cell responses. Human lymph node-on-a-chip testing confirmed it activates human immune cells effectively.
The technology eliminates the strict cold-chain storage that limits mRNA vaccine distribution in under-resourced regions. Lead researcher Yang Claire Zeng has founded DoriNano to bring the platform to clinical trials, with potential applications spanning COVID-19, HIV, Ebola, influenza, and tuberculosis vaccines.
